Launch of Sodali & Co, New Company Formed from Morrow Sodali Following Rapid International Growth
15.7.2024 14:00:00 EEST | Business Wire | Press release
Sodali & Co (the ‘Firm’), formerly Morrow Sodali, a leading global advisory firm, is proud to announce the launch of its new brand, redefining its market presence following the Firm’s rapid international expansion through a series of successful acquisitions.
The new identity recognizes the Firm’s 50-year history and unifies the compelling combination of businesses it has acquired in recent years including GPS; Di Costa Partners; Nestor Advisors; Gryphon Advisors; Citadel Magnus; FrameworkESG; HXE Partners; Powerscourt; Domestique; and Designate. Sodali & Co has the strong investment backing of its majority owner, TPG Growth, the middle market and growth equity platform of TPG, one of the largest asset managers in the world.
Sodali & Co has built an impressive global scale with a team of more than 450 employees serving over 2,000 clients. The Firm has been consistently ranked as the leading global proxy advisor in activist and merger situations. Across its three complementary practice areas of Shareholder Services, Governance & Sustainability, and Strategic Communications, each has specialties covering:
- Shareholder Services covers proxy solicitation services, capital markets intelligence, M&A advisory, fund solutions, and global debt and bondholder solutions
- Governance & Sustainability covers corporate governance, board services, sustainability advisory, and climate advisory
- Strategic Communications covers corporate communications, crisis & special situations, financial & transaction communications, investor relations, public affairs & campaigns, research, and brand & design
The new name derives from the Latin word “Sodalis,” meaning “companion,” and aligns with the Firm’s role as a trusted advisor, helping clients build stakeholder capital through navigating the complex dynamic of shareholder and wider stakeholder interests.
“By bringing together our diverse expertise under one unified entity, we are better positioned to assist our clients’ evolving needs,” said Alvise Recchi, global CEO. “No other firm combines integrated and specialist expertise in shareholder services, governance and sustainability, and strategic communications in the same way as Sodali & Co.”
“This is not just a rebrand. It represents our dedication to building a world-class advisory firm,” said Recchi. “We are unwavering in our commitment to excellence for our clients, supporting them to adapt and thrive in an increasingly volatile, uncertain, complex, and ambiguous world.”
The Sodali & Co brand will be deployed globally immediately.
ABOUT SODALI & CO
Sodali & Co advises corporate clients worldwide as they navigate the complex dynamic of shareholder and stakeholder interests. The firm supports business leaders in anticipating issues, making better, more informed decisions, and communicating more effectively to drive alignment and accelerate performance.
From headquarters in New York, London, and Sydney to offices in major capital markets, Sodali & Co serves over 2,000 corporate clients in 70 countries, across three practice areas of Shareholder Services, Governance & Sustainability, and Strategic Communications. In addition to listed and private companies, its clients include financial institutions, mutual funds, ETFs, stock exchanges, and membership associations.
For more information about Sodali & Co, please visit www.sodali.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715014030/en/
Contacts
Press:
Haley Wright
Global Head of Marketing and Communications
haley.wright@sodali.com
1 202 590 0187
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom